CA3211395A1 - Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide et leurs utilisations - Google Patents

Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide et leurs utilisations Download PDF

Info

Publication number
CA3211395A1
CA3211395A1 CA3211395A CA3211395A CA3211395A1 CA 3211395 A1 CA3211395 A1 CA 3211395A1 CA 3211395 A CA3211395 A CA 3211395A CA 3211395 A CA3211395 A CA 3211395A CA 3211395 A1 CA3211395 A1 CA 3211395A1
Authority
CA
Canada
Prior art keywords
benzamide
fluoro
dihydroxypropoxy
difluoro
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3211395A
Other languages
English (en)
Inventor
Erwin IRDAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CA3211395A1 publication Critical patent/CA3211395A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne : a) une composition cristalline de forme IV essentiellement pure de N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide ; b) des compositions pharmaceutiques comprenant la composition cristalline de forme IV essentiellement pure de N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide, et, éventuellement, un excipient pharmaceutiquement acceptable ; et c) des méthodes de traitement d'une tumeur, d'un cancer ou d'un trouble de type RASopathie par l'administration de la composition cristalline de forme IV essentiellement pure de N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide à un sujet qui en a besoin.
CA3211395A 2021-02-17 2021-02-17 Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide et leurs utilisations Pending CA3211395A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/018378 WO2022177556A1 (fr) 2021-02-17 2021-02-17 Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3211395A1 true CA3211395A1 (fr) 2022-08-25

Family

ID=74860567

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3211395A Pending CA3211395A1 (fr) 2021-02-17 2021-02-17 Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide et leurs utilisations

Country Status (11)

Country Link
EP (1) EP4294789A1 (fr)
JP (1) JP2024507822A (fr)
KR (1) KR20230148177A (fr)
CN (1) CN117500781A (fr)
AR (1) AR124907A1 (fr)
AU (1) AU2021428932A1 (fr)
CA (1) CA3211395A1 (fr)
IL (1) IL304974A (fr)
MX (1) MX2023009555A (fr)
TW (1) TW202245746A (fr)
WO (1) WO2022177556A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
EP1682495A1 (fr) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Forme polymorphe du i n /i - (r)-2,3-dihydroxy-propoxy|-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
WO2006134469A1 (fr) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Procedes de preparation d'un inhibiteur de mek

Also Published As

Publication number Publication date
AU2021428932A1 (en) 2023-09-21
WO2022177556A1 (fr) 2022-08-25
JP2024507822A (ja) 2024-02-21
IL304974A (en) 2023-10-01
EP4294789A1 (fr) 2023-12-27
KR20230148177A (ko) 2023-10-24
TW202245746A (zh) 2022-12-01
CN117500781A (zh) 2024-02-02
MX2023009555A (es) 2023-11-10
AR124907A1 (es) 2023-05-17

Similar Documents

Publication Publication Date Title
US12037306B2 (en) Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
EP3656765B1 (fr) Sels ou co-cristaux de 3-(3-dimethylamino-1-éthyl-2-méthyl-propyl)-phénol
US12090128B2 (en) Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof
US9073899B2 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
JPS636058B2 (fr)
JP2024517431A (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
TW202245745A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之可分散調配物及其用途
CA3211395A1 (fr) Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide et leurs utilisations
US20110269838A1 (en) Novel processes and pure polymorphs
CA2164296C (fr) Chimie heterocyclique
US8754129B2 (en) Crystalline vorinostat form VI
US20220089550A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
US10611772B2 (en) Crystalline form of Ribociclib succinate
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
JPH03163079A (ja) キサンチン誘導体、それらを有効成分とする気管支拡張剤及び脳機能改善剤